Abstract
The proposal of this work was to investigate the effect of the radioactive (NH3)2PtCl2, cis-diamminedichloroplatinum (II) or CDDP* on malignant glioma cells and verify if the low-dose continuous internal radio-chemotherapy would be able to produce additive effects. The antitumoral activity of CDDP* and the non labeled cisplatin, CDDP, were evaluated in glioblastoma. Cisplatin was cytotoxic for glioblastoma cells in a dose dependent manner. Treatment with CDDP*, (IC50 = 1.75 ± 0.07 μM), proved to be more potent than using just CDDP, (IC50 = 4.96 ± 0.40 μM). These results suggest that cisplatin is a very potent radiosensitizer evoking a supra additive effect. Internal radio-chemotherapy treatment based on CDDP* may be useful alternative to reduce the drug concentration required for effective inhibition of glioblastoma growth.
Similar content being viewed by others
References
Levin VA, Leibel, S (1993) In: De Vita VT, Hellman S, Rosenberg SA (eds). Cancer: principles and practice of oncology, 4th edn. Lippincott, Philadelphia, p 883
Winger MJ, MacDonald DR, Cairncross JGJ (1989) Int J Radiat Oncol Biol Phys 71:487
Rosenberg B, Van Camp L, Trosko JE, Mansour VH (1969) Nature 222:385
Al-Sarraf M, Amer MH, Vaishampayan G, Loh J, Weaver A (1979) Int J Radiat Oncol Biol Phys 5:1421
Bachaud JM, Chatelen E, Canal P, Albin N, Yardeni E, David JM, Serrano E, Daly-Schveitzer N (1997) Am J Clin Oncol 20:1
Gorodetsky R, Mou X, Levy-Agababa F, Vexler A (1998) Int J Cancer 75:635
Wheeler RH, Spencer S (1995) Infus Chemother 5:61
Chatal JF, Hoefnagel CA (1999) Lancet 354:931
Zamble DB, Lippard SJ (1995) Trends in Biochem Sci 20:435
Areberg J, Wennerberg J, Jonhsson A, Norrgren K, Mattsson S (2001) Int J Radiat Oncol Biol Phys 49:827
Areberg J, Björkman S, Einarsson L, Frankenberg B, Lundqvist H, Mattsson S, Norrgren K, Scheike O, Wallin R (1999) Acta Oncol 38:221
Akaboshi M, Tanaka Y, Sumino T, Takada J, Kawai K (1998) J Radioanal Nucl Chem 236:145
Junior ADC, Abrantes FM, Menezes MA, Leal AS, Oliveira MC (2005) Braz Arch Biol Technol 48:85
Soares DCF, Menezes MABC, Santos RG, Ramaldes GA (2010) J Radioanal Nucl Chem 284:315
Soares DCF, Oliveira MC, Santos RG, Andrade MS, Vilela JMC, Cardoso VM, Ramaldes GA (2011) Eur J Pharm Sci 42:462
Leal AS, Júnior ADC, Abrantes FM, Menezes MABC, Ferraz V, Cruz TS, Cardoso VN, Oliveira MC (2006) Appl Rad Isot 64:178
Freshney RI (2000) Culture of animal cells: a manual of basic technique. Wiley-Liss, Canada
Okada H, Mak TW (2004) Nat Rev Cancer 4:592
Millau JF, Bastien N, Drouin R (2008) Mutat Res 681:118
Khan ZA, Jonas SK, Le-Marer N, Patel H, Wharton RQ, Tarragona A, Ivison A, Allen-Mersh TG (2000) Clin Cancer Res 6:3499
Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B (1990) Science 249:912
Zambetti GP (2005) The p53 tumor suppressor pathway and cancer. Springer, New York
Choi EK, Roberts KP, Griffin RJ, Han T, Park H, Song CW, Park HJ (2004) Int J Radiat Oncol Biol Phys 60:1264
Burger H, Nooter K, Boersma AWM, Kortland CJ, Van den Berg AP, Stoter G (1998) Int J Radiat Oncol Biol Phys 4:415
Wilkins DE, Ng CE, Raaphorst GP (1996) Int J Radiat Oncol Biol Phys 36:105
Fukotomi J, Fukuda A, Fukuda S, Hara M, Terada A, Yishida M (2006) Life Sci 80:254
Acknowledgment
The authors thank the CNPq and FAPEMIG for their financial support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soares, M.A., Mattos, J.L., Pujatti, P.B. et al. Evaluation of the synergetic radio-chemotherapy effects of the radio labelled cisplatin for the treatment of glioma. J Radioanal Nucl Chem 292, 61–65 (2012). https://doi.org/10.1007/s10967-011-1414-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10967-011-1414-2